NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS) Revenue
Annual & quarterly revenue history · segment & region breakdown
NAMS · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsNewAmsterdam Pharma Company N.V. trailing twelve-month (TTM) revenue is $0.02B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
Compare revenue vs peers
BiotechnologyCompare NAMS revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income NewAmsterdam Pharma Company N.V. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
NewAmsterdam Pharma Company N.V. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from NewAmsterdam Pharma Company N.V.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NAMS revenue · 4 questionsNAMS's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · NewAmsterdam Pharma Company N.V. SEC filings · GAAP · NewAmsterdam Pharma Company N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026